FDA leadership overhaul amid commissioner exodus. The U.S. Food and Drug Administration has reshuffled its top drug and biologics regulators following the departure of Commissioner Marty Makary. Tracy Beth Høeg and Katherine Szarama have left their acting director positions overseeing the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research respectively. Michael Davis and Karim Mikhail will assume these critical roles. These divisions regulate prescription drugs and vaccines, overseeing products accounting for roughly 20 percent of all consumer spending. The leadership changes represent continued turnover at the FDA under the Trump administration, with multiple personnel shifts across key positions in recent months. The administration plans to nominate a permanent commissioner within weeks, pending Senate confirmation.
